Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
99 hedge funds and large institutions have $267M invested in Adverum Biotechnologies in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 21 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
5% more funds holding
Funds holding: 94 → 99 (+5)
9% more call options, than puts
Call options by funds: $7.25M | Put options by funds: $6.68M
0.33% more ownership
Funds ownership: 7.27% → 7.6% (+0.33%)
51% less capital invested
Capital invested by funds: $549M → $267M (-$282M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$37.5M |
| 2 |
O
OrbiMed
New York
|
+$23.1M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$16.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.26M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$8.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$22.5M |
| 2 |
JP Morgan Chase
New York
|
-$18.6M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$14.1M |
| 4 |
Renaissance Technologies
New York
|
-$13.1M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$9.67M |
ADVM Hedge Fund Activity: Q3 2019 in Review
99 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2019, worth a combined $267M — down 51% from $549M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ADVM positions and 21 closed out — a net gain of 5 holders — while 35 added to existing stakes and 21 trimmed.
The largest buyer was State Street, adding an estimated $37.5M. The largest seller was Adage Capital Partners, cutting an estimated $22.5M.
- 99 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2019, up from 94 in Q2 2019.
- Funds reported $267M of Adverum Biotechnologies stock for Q3 2019, down 51% quarter-over-quarter.
- 26 funds opened new Adverum Biotechnologies positions in Q3 2019 and 21 closed out, a net change of +5 holders.
- The largest Adverum Biotechnologies buyer in Q3 2019 was State Street, an estimated $37.5M added.
- The largest Adverum Biotechnologies seller in Q3 2019 was Adage Capital Partners, an estimated $22.5M sold.
Based on aggregated 13F filings for Q3 2019.